• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估心脏生物标志物升高与 COVID-19 感染严重程度的关系:一项荟萃分析。

Assessing the Elevation of Cardiac Biomarkers and the Severity of COVID-19 Infection: A Meta-analysis.

机构信息

Larkin University.

出版信息

J Pharm Pharm Sci. 2020;23:396-405. doi: 10.18433/jpps31501.

DOI:10.18433/jpps31501
PMID:33086028
Abstract

UNLABELLED

  • Purpose: Since December 2019, coronavirus disease 2019 infection has become a global pandemic. The cases of Coronavirus Disease 2019 (COVID-19)-related acute cardiac injury with unknown pathophysiologic mechanism has become increasingly prevalent. However, it is not yet understood how the extent of cardiac injury differs with the intensity of viral infection.  In the current study, we aimed to assess the association between elevated cardiac biomarkers and the severity of COVID-19 infection.

METHODS

A systematic literature search was performed across PubMed and Embase databases from December 1, 2019 to July 10, 2020, to identify studies that reported cardiac biomarkers of troponin (TnI) and creatine kinase-myocardial band (CK-MB) in patients with COVID-19. These studies compared non-severe patients with severe patients, or survivors with non-survivors or medical patients with critically ill patients. The data were extracted for TnI, CK-MB, N-terminal-brain natriuretic peptide (NT-BNP), D-dimer, and lactate dehydrogenase (LDH), C-reactive protein (CRP), and interleukin 6 (IL-6). Wherever possible, the data were pooled for meta-analysis (Review Manager, RevMan. version 5.3) with standard or weighted mean or median difference and corresponding 95% confidence intervals (95% CI).

RESULTS

A total of 25 studies involving 5,626 patients were included in the present analysis. More severe COVID-19 infection was found to be associated with higher mean values of TnI (-0.54 [-0.72, -0.36]) (ng/mL), CK-MB (-1.55 [-2.23, -0.88]) (ng/mL) and (-4.75 [-13.31, 3.82]) (units/L), NT-BNP (-815.7 [-1073.97, -557.42]) (pg/mL), D-dimer (-1.4 [-2.04, -0.77]) (mcg/mL), and LDH (-176.59 [-224.11, -129.06]) (units/L), as well as CRP (-64.03 [-68.88, -59.19]) (mg/L) and IL-6 (-22.59 [-29.39, -15.79]) (pg/mL).

CONCLUSIONS

There is significant association between elevated cardiac biomarkers and the severity of COVID-19, which underlines the increased risk of acute cardiac injury with more severe viral infection. This highlights the need to understand the cardiac history among the COVID-19 patients during initial assessment and for monitoring.

摘要

目的

自 2019 年 12 月以来,新型冠状病毒疾病 2019 感染已成为全球大流行。与新型冠状病毒疾病 2019(COVID-19)相关的急性心脏损伤的病例,其未知的病理生理机制变得越来越普遍。然而,目前尚不清楚心脏损伤的程度与病毒感染的强度有何不同。在本研究中,我们旨在评估升高的心脏生物标志物与 COVID-19 感染严重程度之间的关系。

方法

从 2019 年 12 月 1 日至 2020 年 7 月 10 日,我们对 PubMed 和 Embase 数据库进行了系统的文献检索,以确定报告 COVID-19 患者肌钙蛋白(TnI)和肌酸激酶-MB(CK-MB)心脏生物标志物的研究。这些研究比较了非重症患者与重症患者、幸存者与非幸存者或医疗患者与危重症患者。提取 TnI、CK-MB、N 末端脑利钠肽(NT-BNP)、D-二聚体和乳酸脱氢酶(LDH)、C 反应蛋白(CRP)和白细胞介素 6(IL-6)的数据。在可能的情况下,使用标准或加权平均值或中位数差异和相应的 95%置信区间(95%CI)进行荟萃分析(Review Manager,RevMan. version 5.3)。

结果

本分析共纳入 25 项研究,涉及 5626 例患者。结果发现,更严重的 COVID-19 感染与 TnI(-0.54[-0.72,-0.36])(ng/mL)、CK-MB(-1.55[-2.23,-0.88])(ng/mL)和(-4.75[-13.31,-0.72])(单位/L)、NT-BNP(-815.7[-1073.97,-557.42])(pg/mL)、D-二聚体(-1.4[-2.04,-0.77])(mcg/mL)和 LDH(-176.59[-224.11,-129.06])(单位/L)的平均水平升高,以及 CRP(-64.03[-68.88,-59.19])(mg/L)和 IL-6(-22.59[-29.39,-15.79])(pg/mL)呈显著相关。

结论

升高的心脏生物标志物与 COVID-19 的严重程度之间存在显著关联,这突显了更严重的病毒感染导致急性心脏损伤的风险增加。这强调了在初始评估和监测期间,需要了解 COVID-19 患者的心脏病史。

相似文献

1
Assessing the Elevation of Cardiac Biomarkers and the Severity of COVID-19 Infection: A Meta-analysis.评估心脏生物标志物升高与 COVID-19 感染严重程度的关系:一项荟萃分析。
J Pharm Pharm Sci. 2020;23:396-405. doi: 10.18433/jpps31501.
2
Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review.COVID-19 住院患者中与严重疾病或 ICU 入院和死亡相关的心脏损伤:一项荟萃分析和系统评价。
Crit Care. 2020 Jul 28;24(1):468. doi: 10.1186/s13054-020-03183-z.
3
The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis.2019 新型冠状病毒对心脏损伤的影响:系统评价和荟萃分析。
Prog Cardiovasc Dis. 2020 Jul-Aug;63(4):518-524. doi: 10.1016/j.pcad.2020.04.008. Epub 2020 Apr 16.
4
Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.心脏生物标志物、心脏损伤以及与 2019 年冠状病毒病(COVID-19)严重疾病和死亡率相关的合并症:系统评价和荟萃分析。
Immun Inflamm Dis. 2021 Dec;9(4):1071-1100. doi: 10.1002/iid3.471. Epub 2021 Aug 18.
5
Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies.在 2019 冠状病毒病(COVID-19)感染患者中,心脏损伤与严重结局和死亡相关:一项观察性研究的系统评价和荟萃分析。
Eur Heart J Acute Cardiovasc Care. 2020 Sep;9(6):665-677. doi: 10.1177/2048872620937165. Epub 2020 Jun 21.
6
Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19).新冠肺炎(COVID-19)重型患者的心脏损伤。
BMC Cardiovasc Disord. 2020 Nov 10;20(1):479. doi: 10.1186/s12872-020-01758-w.
7
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19.早期检测升高的心脏生物标志物以优化 COVID-19 患者的风险分层。
Heart. 2020 Oct;106(19):1512-1518. doi: 10.1136/heartjnl-2020-317322. Epub 2020 Aug 14.
8
Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病(COVID-19)住院儿科患者的临床和免疫特征。
JAMA Netw Open. 2020 Jun 1;3(6):e2010895. doi: 10.1001/jamanetworkopen.2020.10895.
9
Coronavirus disease 2019: a comprehensive review and meta-analysis on cardiovascular biomarkers.新型冠状病毒病 2019:心血管生物标志物的全面综述和荟萃分析。
Curr Opin Cardiol. 2021 May 1;36(3):367-373. doi: 10.1097/HCO.0000000000000851.
10
[Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes].[新型冠状病毒肺炎合并高血压、冠心病或糖尿病患者的死亡风险因素]
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Jun 18;52(3):420-424. doi: 10.19723/j.issn.1671-167X.2020.03.004.

引用本文的文献

1
Upregulation of the MAP2K4 gene triggers endothelial-mesenchymal transition in COVID-19.MAP2K4基因的上调引发了新冠肺炎中的内皮-间充质转化。
Mol Biol Rep. 2025 Jan 31;52(1):180. doi: 10.1007/s11033-025-10289-6.
2
Cardiac Magnetic Resonance Imaging of COVID-19-Associated Cardiac Sequelae: A Systematic Review.新冠病毒相关心脏后遗症的心脏磁共振成像:一项系统综述
Rev Cardiovasc Med. 2022 Nov 30;23(12):389. doi: 10.31083/j.rcm2312389. eCollection 2022 Dec.
3
Cardiac Injury in COVID-19: A Systematic Review of Relevant Meta-Analyses.
2019冠状病毒病中的心脏损伤:相关荟萃分析的系统评价
Rev Cardiovasc Med. 2022 Dec 12;23(12):404. doi: 10.31083/j.rcm2312404. eCollection 2022 Dec.
4
Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.在标准治疗基础上加用巴瑞替尼或托珠单抗的住院COVID-19患者的临床结局
Diseases. 2024 May 20;12(5):107. doi: 10.3390/diseases12050107.
5
COVID-19 Associated Cardiovascular Disease-Risks, Prevention and Management: Heart at Risk Due to COVID-19.新型冠状病毒肺炎相关心血管疾病——风险、预防与管理:因新型冠状病毒肺炎而面临风险的心脏
Curr Issues Mol Biol. 2024 Feb 29;46(3):1904-1920. doi: 10.3390/cimb46030124.
6
Cardiac Parameters Better Predict ICU Admission and Short-Term Mortality in Hospitalized Patients With COVID-19.心脏参数能更好地预测COVID-19住院患者的重症监护病房(ICU)入住率和短期死亡率。
Cureus. 2023 Sep 28;15(9):e46141. doi: 10.7759/cureus.46141. eCollection 2023 Sep.
7
The COVID-19 Pandemic and Coronary Heart Disease: the Next Surge.COVID-19 大流行与冠心病:下一波浪潮。
Curr Atheroscler Rep. 2023 Sep;25(9):559-569. doi: 10.1007/s11883-023-01131-0. Epub 2023 Aug 2.
8
COVID19 biomarkers: What did we learn from systematic reviews?COVID19 生物标志物:系统评价给我们带来了哪些启示?
Front Cell Infect Microbiol. 2022 Dec 13;12:1038908. doi: 10.3389/fcimb.2022.1038908. eCollection 2022.
9
Cardiac Manifestations in Patients with COVID-19: A Scoping Review.新型冠状病毒肺炎患者的心脏表现:范围综述。
Glob Heart. 2022 Jan 12;17(1):2. doi: 10.5334/gh.1037. eCollection 2022.
10
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management.2 型糖尿病相关心力衰竭:筛查、诊断与管理的最新观点。
Cardiovasc Diabetol. 2021 Nov 6;20(1):218. doi: 10.1186/s12933-021-01408-1.